Bi/ond

Achieve accurate disease models and more personalized medicine, by recreating human physiology and pathology in a 3D model. Bi/onds customizable Organ-on-Chips (OOCs) are built to outperform the limitation of standard in vitro assays. In the early phase of drug testing, Petri dishes and animals can fall short of predicting what happens inside the human body. Bi/ond is where biology meets engineering : our intimate working relationship with biologists helped realize the supportive role engineering can play in generating reproducible and accurate biological models. We develop a lab technology for dynamic cell culture environments that allow for more precise drug testing...

Chip,lifescience,organoids,organonchip,microfluidic,microfabrication,in vitro,innovation,mps,biotech,3d modelling,cancer research,skeletal muscle,tumor tissue,3rs,personalized medicine,animal free research,cancer biopsy,disease models,cro,toxicology,and pharmaceutical

Bi/ond operates in the Biotechnology research industry.

Bi/ond's revenue is 11m - 100m

Bi/ond has 11 - 50 employees.